[1]褚春沐.多巴丝肼联合普拉克索治疗帕金森的疗效及不良反应研究[J].医学信息,2022,35(18):112-114.[doi:10.3969/j.issn.1006-1959.2022.18.030]
　CHU Chun-mu.Study on Efficacy and Adverse Reactions of Dopazide Combined with Pramipexole in Treatment of Parkinson’s Disease[J].Journal of Medical Information,2022,35(18):112-114.[doi:10.3969/j.issn.1006-1959.2022.18.030]
点击复制

多巴丝肼联合普拉克索治疗帕金森的疗效及不良反应研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年18期
页码:
112-114
栏目:
药物与临床
出版日期:
2022-09-15

文章信息/Info

Title:
Study on Efficacy and Adverse Reactions of Dopazide Combined with Pramipexole in Treatment of Parkinson’s Disease
文章编号:
1006-1959（2022）18-0112-03
作者:
褚春沐
（佳木斯市中心医院神经内科，黑龙江 佳木斯 154002）
Author(s):
CHU Chun-mu
(Department of Neurology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
多巴丝肼; 普拉克索; 帕金森; 过氧化氢酶; 帕金森病指数评分
Keywords:
Dobutamine; Pramipexole; Parkinson; Catalase; Parkinson’s disease index score
分类号:
R742.5
DOI:
10.3969/j.issn.1006-1959.2022.18.030
文献标志码:
A
摘要:
目的 研究多巴丝肼联合普拉克索治疗帕金森病的疗效及不良反应。方法 选取2020年5月-2021年5月在我院诊治的74例帕金森患者为研究对象，采用随机数字表法分为对照组和观察组，各37例。对照组采用多巴丝肼治疗，观察组在对照组基础上联合普拉克索治疗，比较两组治疗总有效率、帕金森病指数评分、日常生活能力（PDQ-39）评分、血清过氧化氢酶（CAT）、白细胞介素-1β（IL-1β）水平以及不良反应发生情况。结果 观察组治疗总有效率为94.59%，高于对照组的81.08%（P＜0.05）；两组帕金森病指数、PDQ-39评分均低于治疗前，且观察组低于对照组（P＜0.05）；两组血清CAT水平均高于治疗前，IL-1β低于治疗前，且观察组CAT高于对照组，IL-1β水平低于对照组（P＜0.05）；观察组不良反应发生率低于对照组，差异无统计学意义（P＞0.05）。结论 多巴丝肼联合普拉克索治疗帕金森临床效果突出，可提高治疗总有效率，降低不良反应，改善患者帕金森指数评分，提高其日常生活能力及血清CAT水平，降低IL-1β水平，值得临床应用。
Abstract:
Objective To study the efficacy and adverse reactions of dopazide combined with pramipexole in the treatment of Parkinson’s disease.Methods A total of 74 patients with Parkinson’s disease who were treated in our hospital from May 2020 to May 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 37 cases in each group. The control group was treated with benserazide, and the observation group was treated with pramipexole on the basis of the control group. The total effective rate, Parkinson ’s disease index score, daily living ability (PDQ-39) score, serum catalase (CAT), interleukin-1β (IL-1β) level and adverse reactions were compared between the two groups.Results The total effective rate of observation group was 94.59%, which was higher than that of control group 81.08% (P<0.05). The Parkinson’s disease index and PDQ-39 score of the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05). The serum CAT level of the two groups was higher than that before treatment, and the serum IL-1β was lower than that before treatment, and the CAT of the observation group was higher than that of the control group, and the IL-1β was lower than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion The clinical effect of levodopa and benserazide combined with pramipexole in the treatment of Parkinson’s disease is outstanding. It can improve the total effective rate of treatment, reduce adverse reactions, improve the Parkinson ’s index score of patients, improve their daily living ability and serum CAT level, and reduce IL-1β level. It is worthy of clinical application.

参考文献/References:

[1]陈媛,林尤斌,桂树虹,等.银杏内酯注射液联合多巴丝肼和普拉克索对帕金森病患者的临床疗效[J].中成药,2020,42(5):1204-1207.[2]石莺,彭汉芬.多巴丝肼联合普拉克索治疗帕金森症的临床疗效[J].现代诊断与治疗,2018,29(6):864-866.[3]王锐利,王辉,李琛,等.美金刚联合多巴丝肼对帕金森病痴呆预后效果、安全性分析[J].中国医院药学杂志,2019,39(24):2520-2523.[4]中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍学组．中国帕金森病治疗指南(第四版)[J].中华神经科杂志,2020,53(12):973-986.[5]郝世胜,李娟.普拉克索联合多巴丝肼片治疗帕金森病的临床效果评价[J].中国继续医学教育,2017,9(34):87-89.[6]郑宋华.多巴丝肼联合普拉克索治疗帕金森的临床疗效及安全性分析[J].现代医院,2017,17(9):1333-1335.[7]张兰.盐酸普拉克索联合多巴丝肼对帕金森氏病的临床效果[J].包头医学院学报,2017,33(9):74-75.[8]李春梅,郭宏博.盐酸普拉克索联合多巴丝肼对老年帕金森的疗效观察[J].中国老年保健医学,2017,15(4):54-56.[9]焦文文,刘娅萍,柴春艳,等.多巴丝肼联合普拉克索治疗帕金森病的临床疗效[J].现代生物医学进展,2016，16(26):5094-5096,5178. [10]刘文娟,刘太杞.多巴丝肼联合普拉克索对帕金森病的疗效及安全性评价[J].中国继续医学教育,2016,8(22):154-156.[11]白璇.盐酸普拉克索片治疗帕金森病患者的临床疗效[J].中国药物经济学,2016,11(1):23-25.[12]王晓平,罗永杰,吴景芬,等.多巴丝肼联合电针对老年帕金森病患者血清白细胞介素-1β、胱抑素C及血清离子水平的影响[J].中国老年学杂志,2016,36(17):4301-4303．[13]周俊,占达飞,欧小凡,等.氯氮平片联合多巴丝肼片治疗帕金森病伴发精神障碍的临床研究[J].中国临床药理学杂志,2016,32(24):2257-2260．[14]纪新博,顾申红,容琼文,等.盐酸普拉克索配合神经节苷脂对帕金森患者血清炎症因子及运动功能的影响[J].现代中西医结合杂志,2016,25(24):2693-2695.[15]吴曙智,叶华,张旭,等.普拉克索片联合美多芭治疗帕金森病的临床疗效观察[J].中国医院药学杂志,2014,34(15):1294-1297.[16]陈丹.美多芭联合普拉克索对帕金森病的临床疗效及安全性研究[J].河北医学,2018,24(11):1903-1906.[17]魏建刚,张倩,杨建波,等.普拉克索联合卡左双多巴缓释片治疗中晚期帕金森患者运动障碍疗效观察[J].临床合理用药杂志,2017,10(7):18-19.[18]叶竹辉.盐酸司来吉兰联合美多芭治疗中晚期帕金森病的效果评价[J].实用中西医结合临床,2018,18(8):101-102.[19]贝筝,文国强,陈怡.恩他卡朋与普拉克索治疗帕金森病非运动症状的效果:前瞻性随机对照研究[J].中国组织工程研究,2019,23(31):5052-5058.[20]孙绍武.普拉克索联合左旋多巴对晚期帕金森病患者临床症状及负性情绪的影响[J].中国实用神经疾病杂志,2017,20(4):118-120.

相似文献/References:

[1]李 鹏,李爱歆.美多巴联合普拉克索治疗帕金森病的有效性及安全性[J].医学信息,2020,33(09):146.[doi:10.3969/j.issn.1006-1959.2020.09.048]
　LI Peng,LI Ai-xin.The Efficacy and Safety of Madopar Combined with Pramipexole in the Treatment of Parkinson’s Disease[J].Journal of Medical Information,2020,33(18):146.[doi:10.3969/j.issn.1006-1959.2020.09.048]
[2]马晓颖.普拉克索联合多巴丝肼治疗帕金森病的效果及对脑血流量的影响[J].医学信息,2022,35(07):134.[doi:10.3969/j.issn.1006-1959.2022.07.034]
　MA Xiao-ying.Effect of Pramipexole Combined with Dobutazide in the Treatment of Parkinson’s Disease and its Effect on Cerebral Blood Flow[J].Journal of Medical Information,2022,35(18):134.[doi:10.3969/j.issn.1006-1959.2022.07.034]

更新日期/Last Update: 1900-01-01